Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449254
Status:
UNKNOWN
Last Update Posted:
2007-06-05
First Post:
2007-03-16
Brief Title:
Phase 2a Randomized Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults
Sponsor:
Manhattan Pharmaceuticals
Organization:
Manhattan Pharmaceuticals
Study Overview
Official Title:
A Phase 2a Randomized Double-Blind Placebo Controlled Parallel Group Safety and Efficacy Study of Oleoyl-Estrone MP-101 in Male Obese Adults
Status:
UNKNOWN
Status Verified Date:
2007-06
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multi-center multiple-dose randomized double-blind three-arm placebo-controlled study of fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None